Finasteride's effects on prostate cancer are not clear from this text.
Finasteride improves hair but may reduce sperm quality at higher doses.
August 2018 in “Journal of The American Academy of Dermatology” Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.
Adherence to finasteride treatment for prostate issues is generally low.
August 2018 in “Journal of The American Academy of Dermatology” The conclusion is that finasteride is linked to an increased risk of suicidal thoughts and a higher risk of completed suicide when used for hair loss.
15 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride doesn't affect erections much, but may decrease libido in men.
3 citations
,
July 1997 in “The Lancet” Finasteride may increase hair growth and prevent baldness in men, but can cause sexual side effects.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
January 2013 in “Pharmaceutical journal/The pharmaceutical journal”
42 citations
,
December 2007 in “American Journal of Psychiatry” Finasteride may effectively reduce Tourette's syndrome symptoms and improve life quality.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Gut bacteria imbalance may cause Post-Finasteride Syndrome symptoms.
October 2025 in “International Journal of Social health” Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.
January 2009 in “Acta urologica Belgica” Finasteride effectively treats BPH by reducing prostate size and improving symptoms.
January 2012 in “Medical Journal of Babylon”
6 citations
,
April 2004 in “Dermatologic Surgery” Finasteride showed limited hair growth and low patient compliance in treating male pattern baldness.
5 citations
,
April 2011 in “Bioorganic & Medicinal Chemistry Letters” New Finasteride conjugate improves prostate treatment and vital signs in rats.
581 citations
,
October 1998 in “Journal of The American Academy of Dermatology” Finasteride safely and effectively treats male pattern hair loss, but may cause reversible sexual issues and harm male fetuses.
17 citations
,
November 1997 in “Andrology” Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.
4 citations
,
October 2002 in “BJUI” Finasteride treats hair loss but may affect prostate cancer detection.
10 citations
,
January 2012 in “Annals of Dermatology” Finasteride 1.25 mg showed small improvements in hair density and thickness for female pattern hair loss, but more research is needed.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
2 citations
,
January 2008 in “Journal of Pakistan Association of Dermatology” Finasteride 1mg daily effectively increases hair growth and slows hair loss in men with male pattern baldness over two years.
Finasteride may help reduce COVID-19 infection by altering a key gene.
34 citations
,
January 1998 in “European Urology” Finasteride works best in 6 months and lasts 6 years.
October 2006 in “The Lancet Oncology” Finasteride reduces prostate cancer risk but may increase aggressive cancer risk slightly.
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men increases the risk of sexual dysfunction.
44 citations
,
January 2013 in “International Journal of Trichology” Finasteride 5 mg/day effectively treats hair loss in postmenopausal women without hyper-androgenism.
November 2003 in “PubMed”
April 2006 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Oral finasteride, combined with drospirenone, improved hair loss in 62% of premenopausal women, with no reported side effects.
2 citations
,
August 2011 in “Cochrane Database of Systematic Reviews”